natgillin/translations-raw huggingface dataset:
Pioglitazone was devoid of genotoxic potential in a comprehensive battery of in vivo and in vitro genotoxicity assays.
V obsežnem naboru genotoksičnih testov in vivo ter in vitro pioglitazon ni deloval genotoksično.
Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision.
Pioglitazon ne bo vplival na vašo sposobnost upravljanja vozil in strojev, vendar pa morate biti pazljivi, če se vam pojavi zamegljen vid.
Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision.
Pioglitazon ne bo vplival na vašo sposobnost vožnje ali upravljanja strojev, vendar bodite pozorni, če imate motnje vida.
Pioglitazone – oral anti-diabetic medicine used to treat type 2 diabetes mellitus.
Pioglitazon (peroralno zdravilo za zdravljenje sladkorne bolezni tipa 2)
Pioglitazone – tablets used for the treatment of type 2 diabetes mellitus.
Pioglitazon (tablete za zdravljenje sladkorne bolezni tipa 2)
pioglitazone, rosiglitazone, repaglinide, tolbutamide and glipizide (used to treat diabetes),
pioglitazon, rosiglitazon, repaglinid, tolbutamid in glipizid (uporabljajo se za zdravljenje sladkorne bolezni),
PIP Jointsb p-value
PIP sklepib p-vrednost
Piperaquine has an absorption maximum at 352 nm.
Največja absorpcija piperakina je pri 352 nm.
Piperaquine is a bisquinoline, and this class has shown good antimalarial activity against chloroquine- resistant Plasmodium strains in vitro.
Piperakin je biskinolon in ta razred kaže in vitro dobro antimalarično aktivnost proti sevom plazmodija, odpornim na klorokin.
Piperaquine is metabolised by CYP3A4 in vitro.
Encim CYP3A4 in vitro presnavlja piperakin.
Piperaquine is metabolised by, and is an inhibitor of CYP3A4.
Piperakin se presnavlja z encimom CYP3A4 in je pa hkrati zaviralec tega encima.
Piperaquine tetraphosphate is a so-called
Piperakin tetrafosfat je t. i. biskinolon.
Pipette (HDPE)
Kapalka (iz polietilena visoke gostote)
Pipette (plastic)
Pipeta (plastična)
Pipette (PP) with screw
Polipropilenska pipeta s pokrovom z navojem
Pipette (PP) with screw cap (PP)
Polipropilenska pipeta s pokrovom z navojem
Pipette (PP/Alu/PP)
Kapalka (PP/Alu/PP)
Pipette (PP/Alu/PP)
Kapalka PP/Alu/PP)
Pipette (PP/COC) with foil cap (Al/PP)
KAPALKA (PP/COC) S POKROVČKOM IZ FOLIJE (AL/PP)
Pipette 137.5 mg
Merilna kapalka (137,5 mg)
Pipette 275 mg
Merilna kapalka (275 mg)
Pipette 56.25 mg
Merilna kapalka (56,25 mg)
Pipette 625 mg
Merilna kapalka (625 mg)
Pipette cap colour
Barva Pokrovačka merilne kapalke
Pipette cap colour
Barva pokrovčka merilne
Pipette cap colour
Barva Pokrovčka merilne kapalke
PIPETTE LABEL
MERILNA KAPALKA
Pipette size to be used
Merilna kapalka
Pipette size to be used
Velikost kapalke
Pipette size to be used
Velikost merilne kapalke
Pipette size to be used
Vrsta merilne kapalke
PIPF-016 compared treatment with Esbriet 2,403 mg/day to placebo.
V študiji PIPF–016 so primerjali zdravljenje z zdravilom Esbriet 2403 mg/dan s placebom.
Pirfenidone binds to human plasma proteins, primarily to serum albumin.
Pirfenidon se veže na beljakovine človeške plazme, predvsem na serumski albumin.
Pirfenidone is not considered to present a potential risk to surface water, microorganisms and ground water or to sediment-dwelling invertebrates.
Pirfenidon se ne šteje kot potencialno nevaren površinskim vodam, mikroorganizmom in podzemnim vodam oziroma nevretenčarjem, ki živijo v sedimentih.
Pirlimycin hydrochloride equivalent to 50 mg pirlimycin per 10 ml syringe
Pirlimicin hidroklorid, ekvivalentno 50 mg pirlimicina na 10 ml injektor.
piroxicam - used for arthritis
piroksikam – uporablja se za zdravljenje artritisa
PIRSUE 5 mg/ml intramammary solution for cattle
PIRSUE 5 mg/ml intramamarna raztopina za govedo
PIs or NNRTIs) is unlikely.
PI-ji ali NNRTI) ni verjetna.
PIs) unlikely.
PIs).
Pitavastatin
atorvastatin pitavastatin
pite of this, a small increase in cortisol suppression was seen after administration of fixed-dose combination compared to the monoproducts.
Kljub temu so po uporabi kombinacije budezonida in formoterola v fiksnem odmerku opažali blago okrepitev supresije izločanja kortizola v primerjavi z izdelki, ki vsebujejo le po eno učinkovino.
Pitolisant has a plasma half-life of 10-12 hours.
Plazemski razpolovni čas pitolizanta je 10–12 ur.
Pitolisant is contra-indicated in patients with severe hepatic impairment (Child-Pugh C) (see section 4.3).
Pitolizant je kontraindiciran pri bolnikih s hudo okvaro jeter (stopnje C po Child-Pughovi lestvici) (glejte poglavje 4.3).
Pitolisant shows greater than 50% inhibition towards OCT1 (organic cation transporters 1) at 1.33 µM, the extrapolated IC50 of pitolisant is 0.795 µM (see section 4.5).
Pitolizant več kot 50-odstotno zavira OCT1 (organske kationske prenašalce 1) pri 1,33 µM – ekstrapolirana IC50 pitolizanta je 0,795 µM (glejte poglavje 4.5).
Pitting oedema
ljukničasti (pitting) edem
Pitting oedema*
vtisni edem
pitting of blood or nosebleed
izkašljevanje krvi ali krvavitev iz nosu
Pituitary function and hormone levels should be monitored to ensure appropriate hormone replacement.
Za zagotovitev ustreznega nadomeščanja hormonov je treba spremljati delovanje hipofize in vrednosti hormonov.
pituitary gland not working properly – this may cause low blood levels of some hormones that affect the function of the male or female sex organs hearing problems
nepravilno delovanje žleze hipofize – to lahko povzroči nizko koncentracijo nekaterih hormonov, ki vplivajo na delovanje moških ali ženskih spolnih organov težave s sluhom
Pivotal Efficacy Studies:
Ključne študije učinkovitosti:
Pivotal studies included five trials.
Ključne študije obsegajo pet preskušanj.
Pivotal Studies MS-F203 and MS-F204
Osrednji študiji MS-F203 in MS-F204
Pivotal study (07-AVR-123)
Ključna študija (07-AVR-123)
Pivotal Study (N= 25) ZLB03_002CR
Osrednja študija (N = 25) ZLB03 002 CR
Pivotal study of Cerdelga in GD1 patients switching from ERT– Study 02607 (ENCORE)
Ključna študija zdravila Cerdelga pri bolnikih z GD1, ki so na zdravilo prešli z nadomestnega encimskega zdravljenja (ERT) – študija 02607 (ENCORE)
Pivotal study of Cerdelga in treatment-naïve GD1 patients – study 02507(ENGAGE)
Ključna študija zdravila Cerdelga pri bolnikih z GD1, ki predhodno niso bili zdravljeni – študija 02507 (ENGAGE)
Pivotal Study – Study 209 (Core Phase; ITT)
Osrednja študija – študija 209 (osrednja faza; ITT)
Pivotal trials for Prevenar 13 were designed to show that functional OPA antibody responses for the 13 serotypes are non-inferior, and for some serotypes superior, to the 12 serotypes in common with the licensed 23-valent pneumococcal polysaccharide vaccine [1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] one month after vaccine administration.
Ključna preskušanja pri cepivu Prevenar 13 so bila načrtovana z namenom, da bi pokazali, da so odzivi funkcionalnih protiteles OPA za 13 serotipov enakovredni, za nekatere serotipe pa boljši kot pri 12 serotipih, ki so skupni cepivu Prevenar 13 ter odobrenemu 23-valentnemu pnevmokoknemu polisaharidnemu cepivu [1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] 1 mesec po cepljenju.
PIX 301 Overall survival–end of study
Skupno preživetje ob koncu študije PIX 301
Pixuvri (n=70)
Pixuvri (n = 70)
Pixuvri 29 mg powder for concentrate for solution for infusion
Pixuvri 29 mg prašek za koncentrat za raztopino za infundiranje
Pixuvri 29 mg powder for concentrate for solution for infusion pixantrone
Pixuvri 29 mg prašek za koncentrat za raztopino za infundiranje piksantron
Pixuvri belongs to a pharmacotherapeutic group of medicines known as ‘antineoplastic agents’.
Zdravilo Pixuvri spada v farmakoterapevtsko skupino zdravil, znanih kot 'zdravila, ki vplivajo na novotvorbe'.
Pixuvri does not contain anything to prevent the growth of bacteria and it is, therefore, recommended that it be used immediately after reconstitution.
Zdravilo Pixuvri ne vsebuje ničesar, kar preprečuje rast bakterij, zato ga je priporočljivo uporabiti takoj po rekonstituciji.
Pixuvri Dose (mg/m2)
Odmerek zdravila Pixuvri (mg/m2)
Pixuvri has a large volume of distribution of 25.8 l and is approximately 50% bound to plasma proteins.
Zdravilo Pixuvri ima velik volumen porazdelitve, 25,8 l, približno 50 % pa je vezano na beljakovine v plazmi.
Pixuvri has been given ‘conditional approval’.
Zdravilo je pridobilo tako imenovano „pogojno dovoljenje za promet“.
Pixuvri is a cytotoxic agent.
Zdravilo Pixuvri je citotoksično.
Pixuvri is a powder for concentrate for solution for infusion.
Zdravilo Pixuvri je prašek za koncentrat za raztopino za infundiranje.
Pixuvri is given on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles.
Zdravilo Pixuvri se daje 1., 8. in 15. dan vsakega 28-dnevnega cikla, do največ 6 ciklov.
Pixuvri is used to treat adult patients with non-Hodgkin’s B cell lymphoma.
Pixuvri se uporablja za zdravljenje odraslih bolnikov z ne-Hodgkinovim B-celičnim limfomom.
Pixuvri pixantrone
Pixuvri piksantron
Pixuvri should not be administered to patients with an active, severe infection or in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose them to serious infection.
Zdravilo Pixuvri se ne sme dajati bolnikom z aktivnimi hudimi okužbami, bolnikom s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali bolnikom z obstoječimi boleznimi, zaradi katerih bi lahko bili dodatno dovzetni za resne okužbe.
Pixuvri was compared with other chemotherapy treatments in one main study involving 140 adults with aggressive non-Hodgkin’s B cell lymphoma, who had previously received at least two other treatments, and whose cancer had come back or had not responded to treatment.
V eni glavni študiji, ki je zajela 140 odraslih z agresivnim ne-Hodgkinovim B-celičnim limfomom, ki so se predhodno zdravili z vsaj dvema drugima zdraviloma in pri katerih se je rak ponovil ali se ni odzval na zdravljenje, so zdravilo Pixuvri primerjali z drugimi kemoterapevtiki.
Pixuvri was shown to be beneficial in patients with aggressive non-Hodgkin’s B cell lymphoma: 20% of patients responded completely to Pixuvri (14 out of 70 patients) compared with 5.7% of patients receiving other agents (4 out of 70 patients).
Zdravilo Pixuvri je izkazalo koristen učinek pri bolnikih z agresivnim ne-Hodgkinovim B-celičnim limfomom: 20 % bolnikov se je popolnoma odzvalo na zdravljenje z zdravilom Pixuvri (14 od 70 bolnikov) v primerjavi s 5,7 % bolnikov, ki so dobivali druge učinkovine (4 od 70 bolnikov).
Pixuvri with food and drink
Zdravilo Pixuvri skupaj s hrano in pijačo
PK (ED 1)
Farmakokinetika (ED 1)
PK analysis in patients of Cav found that 81 % of the subjects treated with the 300 mg once daily dose attained steady state predicted Cav between 500-2,500 ng/mL.
Farmakokinetična analiza pri bolnikih s Cav je pokazala, da je 81 % preiskovancev, zdravljenih z odmerkom 300 mg enkrat na dan, doseglo predvideno Cav v stanju dinamičnega ravnovesja od 500 do 2.500 ng/ml.
PK parameter
Lyfjahvarfabreytur
PK parameters
PK-parametri
PK parameters for Nuwiq (Dose: 50 IU/kg) in adult previously treated patients (age 18- 65 years) with severe haemophilia A (n = 20)
Farmakokinetični parametri za zdravilo Nuwiq (Odmerek: 50 i.e./kg) pri odraslih predhodno zdravljenih bolnikih (starost 18–65 let) s hudo obliko hemofilije A (n = 20)
PK parameters for Nuwiq (Dose: 50 IU/kg) in previously treated children aged 2 to 5 years with severe haemophilia A (n = 13)
Farmakokinetični parametri za zdravilo Nuwiq (Odmerek: 50 i.e./kg) pri predhodno zdravljenih otrocih (starost 6 do 12 let) s hudo obliko hemofilije A (n = 12)
PK parameters from the repeat PK evaluation were similar to those from initial PK.
Farmakokinetični parametri so bili pri večkratnem vrednotenju farmakokinetike podobni izhodiščnim parametrom.
PK Parameters1
FK-parametri1
PK/PD relationship
Razmerje farmakokinetika/farmakodinamika
PK/PD relationships
Razmerje farmakokinetika/farmakodinamika
Place 1-2 teaspoons of the food in a small container (illustration a).
Dajte 1-2 čajni žlički hrane v majhno posodo (slika a).
Place a 26G needle onto an appropriate single-use syringe (max.1 ml).
Na brizgo za enkratno uporabo (največ 1 ml) namestite iglo 26G.
Place a new system on a different skin site
Namestite nov sistem na drug kožni predel.
Place a new system on a different skin site.
nalepite trak na vzdolžne robove
Place a pharmacy label on the bottle that includes the patient’s name, dosing instructions, use by date, name of medicinal product and any other required information to be in compliance with local pharmacy regulations.
Na steklenico nalepite nalepko, ki vključuje bolnikovo ime, navodila za odmerjanje, rok uporabnosti zdravila, ime zdravila in katero koli drugo potrebno informacijo, ki je v skladu z lokalnimi predpisi v lekarni.
Place a pharmacy label on the bottle that includes the patient’s name, dosing instructions, use by date, name of medicinal product and any other required information to be in compliance with local pharmacy regulations.
Na steklenico nalepite nalepko, ki vključuje bolnikovo ime, navodila za odmerjanje, rok uporabnosti zdravila, ime zdravila in katerokoli drugo potrebno informacijo, ki je v skladu z lokalnimi predpisi v lekarni.
Place a thumb and a middle finger on the side tabs
Postavite palec in sredinec na stranska jezička.
Place all used dressings and cleaning materials in a sealed plastic bag and throw them away in your household waste.
Ves porabljeni material za obvezovanje in čiščenje dajte v zapečateno plastično vrečko in ga zavrzite v gospodinjske odpadke.
Place all used needles and syringes into a sharps container (puncture-proof disposable container).
uporabljenje igle in injekcijske brizge odvrzite v zabojnik za ostre predmete;
Place all used needles and syringes into a sharps container (puncture-proof disposable container).
uporabljenje injekcijske igle in injekcijske brizge odvrzite v zabojnik za ostre predmete;
Place all used needles and syringes into a sharps container (puncture‐proof disposable container).
Vse uporabljene igle in brizge zavrzite v vsebnik za ostre odpadke (proti prebadanju varen vsebnik za enkratno uporabo).
Place and hold the vial of the reconstituted suspension on a hard surface.
Vialo z rekonstituirano suspenzijo položimo in pridržimo ob trdi površini.
PLACE AND UNLOCK
2 NAMESTITE IN ODKLENITE
PLACE AND UNLOCK
NAMESTITE IN ODKLENITE
Place each half into separate scintillation vials to which 5 ml LSC cocktail must be added (e.g.
Dajte vsako od obeh polovic v posebno scintilacijsko vialo, ki ste ji dodali 5 ml mešanice LSC (npr.
Place hand on the middle of the pen so that neither the grey cap (1) nor the plum cap (2) is covered.
Roko položite na sredino peresnika, tako da ne zakrivate ne sivega pokrovčka (1) in ne temnomodrega pokrovčka (2).
Place it in your mouth and it will disperse immediately.
Odmerek orodisperzibilne tablete dajte v usta, kjer bo takoj razpadel.
Place mouth over the mouthpiece creating a tight seal.
Z usti tesno objemite ustnik.
Place pre-filled pen on injection site
Napolnjeni injekcijski peresnik približajte mestu injiciranja
Place product vial on a firm, non-skid surface.
Vialo z zdravilom postavite na trdno nedrsečo površino.
Place RebiSmart at a right angle (90°) to the skin.
Namestite RebiSmart pod pravim kotom (90°) na kožo.
Place syringes and vials onto a clean surface.
Odložite injekcijski brizgi in viali na čisto površino.
Place the administration system on the thigh as pictured at the site which you have prepared.
Postavite aplikacijski sistem na razkuženo mesto na stegnu, kot je razvidno na spodnji sliki.
Place the administration system, the alcohol swab and this package leaflet within reach.
V dosegu roke si pripravite aplikacijski sistem, alkoholni robček in to navodilo.
Place the BIO-SET on a flat surface.
BIO-SET postavite na ravno podlago.
Place the blue end of the transfer device on the solvent vial and push straight down until the spike penetrates the rubber stopper and snaps into place.
Postavite modri konec pribora za prenos vehikla na vialo z vehiklom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
Place the calendar card on the top of the plastic tub and push down to snap it into place.
Koledarsko kartico položite na vrh plastičnega vsebnika in jo potisnite navzdol, da se zaskoči na mesto.
Place the cap on the oral dispenser until it clicks.
Zaporko namestite na odmernik, da se zaskoči.
Place the capsule into the capsule chamber.
Kapsulo namestite v vdolbino za kapsulo.
Place the clear end of the transfer device on the powder vial and push straight down until the spike penetrates the rubber stopper and snaps into place.
Položite prozorni konec pribora za prenos vehikla na vialo s praškom in ga potisnite naravnost navzdol, da bo konica prebodla gumijasto zaporko in se zaskočila na svoje mesto.
Place the dosing syringe in your child’s mouth towards the cheek and gently push the plunger down to release the medicine.
Brizgo namestite v otrokova usta, jo usmerite proti licu in z nežnim pritiskom na bat iztisnite zdravilo.
Place the empty sachet and any left over medicine from the mixing cup into a rubbish bag.
Prazno vrečico in morebitni preostanek zdravila iz posodice za mešanje dajte v vrečko za smeti.
Place the filled syringe on the clean, flat surface.
Napolnjeno injekcijsko brizgo položite na čisto in ravno površino.
Place the following on a clean, flat surface
Na čisto, ravno površino položite naslednje:
Place the label on the blister over the words ‘Place day label here’.
Oznako prilepite na pretisni omot čez besede "sem prilepite nalepko z dnevnimi oznakami".
Place the mouthpiece in your mouth and close your lips firmly around it.
Ustnik namestite v usta in ga trdno objemite z ustnicami.
Place the mouthpiece in your mouth and close your lips firmly around the mouthpiece.
Ustnik namestite v usta in ga trdno objemite z ustnicami.
Place the needle at approximately a 45-degree angle to the pinched skin.
Iglo postavite na stisnjeno kožno gubo pod kotom približno 45 stopinj.
Place the needle cover back on the work surface.
Odložite pokrovček igle nazaj na delovno površino.
Place the needle firmly on the tip of the syringe (4).
Iglo trdno namestite na vrh brizge (4).
Place the needle shield (containing the needle) on a clean dry surface, while preparing the syringe.
Medtem ko pripravljate injekcijsko brizgo, položite pokrovček (v katerem je igla) na čisto suho površino.
Place the nozzle in one of your nostrils – see picture g.
Dajte nastavek v eno od nosnic – glejte sliko g.
Place the nozzle in one of your nostrils – see picture g.
Dajte šobo v eno od nosnic – glejte sliko g.
Place the OBIZUR powder vial on a clean, flat, hard surface.
Vialo s praškom zdravila OBIZUR postavite na čisto, ravno in trdno površino.
Place the oral syringe inside the child’s mouth and press the plunger slowly to gently release the medicinal product.
Brizgo za peroralno odmerjanje vstavite v otrokova usta in počasi pritisnite bat, da boste previdno odmerili zdravilo.
Place the oral syringe inside the child’s mouth and press the plunger slowly to gently release the medicine.
Brizgo za peroralno odmerjanje vstavite v usta otroka in počasi pritisnite bat, da boste previdno odmerili zdravilo.
Place the oral syringe tip between the dog’s cheek and gum and press the plunger until the ring-stop causes the plunger to stop.
Postavite konico oralne brizge med lice in dlesen psa ter pritiskajte bat, dokler ga zaporni obroček ne ustavi.
Place the outer needle cap on a flat surface.
Zunanji pokrovček igle postavite na ravno površino.
Place the patch underneath your clothing.
Obliž namestite pod oblačila.
Place the pen back in the refrigerator and contact your doctor or pharmacist..
Položite peresnik nazaj v hladilnik in se obrnite na vašega zdravnika ali farmacevta.
Place the pen cover on a flat, hard surface.
Pokrovček napolnjenega injekcijskega peresnika položite na ravno, trdno površino.
Place the pen into the clean, empty cup to keep the clear cartridge pointing up.
Položite peresnik v čist, prazen kozarec, tako da bo prozorni vložek obrnjen navzgor.
Place the pen over your chosen injection site.
Napolnjen injekcijski peresnik položite čez izbrano mesto injiciranja.
Place the Plegridy pen on your chosen injection site.
Injekcijski peresnik zdravila Plegridy namestite na izbrano mesto injiciranja.
Place the powder vial (green cap) on a flat surface.
Vialo s praškom (zelena zaporka) položite na ravno površino.
Place the powder vial on a flat surface.
Vialo s praškom položite na ravno površino.
Place the powder vial on an even surface and hold it.
Postavite vialo s praškom na ravno površino in jo držite.
Place the pre-filled pen on the injection site
Napolnjeni injekcijski peresnik približajte mestu injiciranja
Place the prescribed number of tablets in a glass or cup (up to 120 ml) of water and stir until dissolved.
Predpisano število tablet dajte v kozarec ali skodelico z vodo (do 120 ml) in mešajte dokler se ne raztopijo.
Place the prescribed number of tablets in a glass or cup of water as accurately described below and stir until dissolved.
Predpisano število tablet je treba dati v kozarec ali lonček z vodo kot je natančno opisano spodaj in mešati, dokler se ne raztopijo.
Place the prescribed number of tablets in the medicine cup.
V lonček za zdravilo dajte predpisano število tablet.
Place the required dose (preferably broken if Siklos 1000 mg tablet is used) in a teaspoon and add some water.
Potrebni odmerek (najbolje zlomljen, če uporabljate Siklos 1000 mg tablete) dajte na čajno žličko in dolijte nekoliko vode.
Place the solvent vial on a flat surface and insert the white end of the transfer device into the center of the stopper of the upright solvent vial (blue cap).
Vialo z vehiklom položite na ravno površino in vstavite beli konec pripomočka za prenos v središče zamaška pokonci stoječe viale z vehiklom (modra zaporka).
Place the strip into a chromatography chamber containing 1 mL of acetone as the developing solvent.
Listič položite v komoro za kromatografijo, ki vsebuje 1 ml acetona kot topila za razvijanje.
Place the syringe in front of one of the nostrils and carefully administer the whole contents of the syringe into the nasal cavity via this nostril.
Brizgo držite pred nosnico in njeno vsebino previdno vbrizgajte v nosno votlino.
Place the syringe nozzle firmly into the opening of the bottle.
Odprtino brizge trdno namestite v odprtino steklenice.
Place the syringe on a flat surface.
Brizgo položite na ravno površino.
Place the syringe on your clean work surface.
Položite brizgo na čisto delovno površino.
Place the syringe tip against the inside of the patient’s cheek.
Položite konico brizge ob notranjost bolnikovega lica.
Place the syringe tip at the bottom of the mixing cup.
Dajte konico brizge na dno posodice za mešanje.
Place the syringe tip into the liquid.
Dajte konico brizge v tekočino.
Place the tablet in the dog’s mouth.
Daj tableto živali v gobec.
Place the tablet on your tongue until it melts and is easy to swallow.
Položite tableto na jezik, da se raztopi in jo je lahko pogoltniti.
place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
da tablete v 5 ml (1 čajno žličko) vode ali toliko vode, da so tablete prekrite z vodo,
place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine,
date v 5 ml (1 čajna žlička) ali toliko vode, ta so tablete pokrite,
Place the tablets in a glass or cup (120 to 240 ml) of water and stir until dissolved.
Tablete dajte v kozarec ali skodelico z vodo (120 do 240 ml) in mešajte dokler se ne raztopijo.
Place the tip of the oral dispenser in the child’s mouth along in the inner cheek on either the right or left side.
Konico odmernika dajte otroku v usta in jo usmerite v notranjo stran otrokovega lica, na desni ali levi strani.
Place the tip of the oral syringe onto the tip of the gastrostomy/nasogastric tube.
Položite vrh/konico peroralne brizge na vrh/konico gastrostome/nazogastrične sonde.
Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin.
Položite konico merilne kapalke na kožo in jo rahlo stisnite, da nanesete odgovarjajočo količino zdravila neposredno na kožo.